| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8680548 | Alzheimer's & Dementia: Translational Research & Clinical Interventions | 2017 | 5 Pages |
Abstract
Assuming the improvement at first follow-up observed in this trial represents PEs, the rate of change from the second assessment forward is a more accurate representation of symptom progression in this population and is the appropriate reference point for describing treatment effects characterized as percent slowing of symptom progression; failure to accommodate this leads to an oversized clinical trial. We conclude that PEs are an important potential consideration when planning future trials.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Diane M. Jacobs, M. Colin Ard, David P. Salmon, Douglas R. Galasko, Mark W. Bondi, Steven D. Edland,